Pentoxifylline vaginal - Prokrea

Drug Profile

Pentoxifylline vaginal - Prokrea

Alternative Names: Pentoxifylline vaginal; PKB-171

Latest Information Update: 17 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator PROCREA BioSciences
  • Class Anticoagulants; Antithrombotics; Infertility therapies; Small molecules; Vascular disorder therapies; Vasodilators; Xanthines
  • Mechanism of Action Phosphoric diester hydrolase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Male infertility

Most Recent Events

  • 17 Apr 2017 Chemical structure information added
  • 23 Mar 2017 Prokrea has patent protection for pentoxifylline vaginal (Prokrea's Website, March 2017)
  • 17 Mar 2017 Phase-II clinical trials in Male infertility in Spain (Vaginal) (EudraCT2016-003993-42)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top